The EMBLA group - Enabling Microtechnologies for Biomedical and Life science Applications
The EMBLA group is led by Dr. Maria Tenje and comprises researchers with backgrounds in material science, nanotechnology, chemistry and biology. The research activities of EMBLA are focused on single-cell-analysis and organs-on-chip.
We have an interdisciplinary character of our projects and we use microfabrication techniques combined with microfluidics to develop new platforms for visualisation and characterisation of cells to learn more about the human biology. We address both fundamental research questions and develop microsystems that in the near future could find clinical and industrial applications.
The Swedish Research Council Formas, Knut and Alice Wallenberg foundation (Wallenberg Fellowship) and the European Research Council (ERC Starting Grant).
Organs-on-chip is a quickly growing field in microfluidics, with the aim to reduce the need for animal testing and improved preclinical trials. Our research activities are mainly focused on realising novel culture scaffolds for improved in vivo resemblance of the in vitro models.
There are several biological barriers with the purpose to protect our bodies from harmful substances from the environment. The effectivenss of these barriers does however present real challenges for effecient drug delivery as the medicines cannot enter the body. The solution is to culture cells with a specific origin to create in vitro models of different organs. We anticipate that these models can serve as research tools for drug development in the near future.
There is a great need of systems that can analyse single cells, instead of looking at the response of whole populations, in many biological processes. Our reserach if focused on realising different technological platforms for this task.
We develop droplet-based microfluidic systems where cells and particles can be manipulated and analysed. Single cells can be encapsulated in individual droplets, acting as reservoirs during the assay. We also develop minaturised systems to manipulate bacteria for large-scale genomic screening.